Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.
EP. 1: Current Approaches to Assessing Patients With CLL
Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.
EP. 2: Prognostic Testing and Chemoimmunotherapy Use in CLL
The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.
EP. 3: Diagnostic Testing for Newly Diagnosed CLL
Recommendations for conducting imaging scans and biopsies to help guide the treatment of newly diagnosed chronic lymphocytic leukemia.
EP. 4: Repeat Prognostic Testing in CLL
Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.
EP. 5: Frontline Treatment Approaches in CLL
Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.
EP. 6: Future Directions Treating CLL With Novel Therapy-Based Regimens
Considerations for using novel fixed-duration regimens and triplet therapy to treat patients with chronic lymphocytic leukemia.
EP. 7: MRD Testing in CLL
Circumstances for which MRD testing may be considered for patients with chronic lymphocytic leukemia.
EP. 8: Optimizing Testing Rates in CLL: Q&A
Drs Alexey Danilov and Anthony Mato respond to a variety of questions pertaining to the assessment and treatment of patients with chronic lymphocytic leukemia.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab